Longevity Research – Ayurved Healing

Telomerase Activation by Rasayanas: What Anti-Aging Genomics Reveals

Dr. Meera Iyer — Sun, 14 Jun 2026 07:30:00 +0000

In 2009, Elizabeth H. Blackburn, Carol W. Greider, and Jack W. Szostak shared the Nobel Prize in Physiology or Medicine for discovering how chromosomes are protected by telomeres and the enzyme telomerase. That discovery established a central part of chromosome biology, but it did not make telomere length a simple meter of whole-body age or prove that raising telomerase is a safe route to longevity. Claims about herbs and telomeres must therefore distinguish cell studies, animal work, human outcomes, and classical Ayurveda.

Human telomeres contain repeated TTAGGG DNA sequences and protective proteins at chromosome ends. They generally shorten during repeated division of many somatic cells, and critically short or dysfunctional telomeres can contribute to senescence, apoptosis, or genomic instability. Telomerase adds telomeric repeats, but its activity is low in most normal somatic tissues and commonly increased in cancer cells. Telomere length is associated with age, yet a single measurement is only a rough estimate of biological ageing and varies by tissue, cell composition, inherited factors, exposures, and assay method.

Ayurveda approaches ageing through Rasayana, not through telomere biology. Charaka Samhita, Chikitsa Sthana 1.1.7-8, describes benefits traditionally attributed to properly used Rasayana, including longevity, memory, intellect, health, youthfulness, complexion, voice, and strength, and defines it as a means of obtaining excellent quality of rasa and the other dhatus. This is a classical therapeutic framework; it should not be retrospectively translated as “telomerase activation,” “DNA repair,” or “epigenetic rejuvenation” unless those mechanisms are demonstrated experimentally.

Ashwagandha: Direct Telomere Evidence Is In Vitro

The strongest direct telomerase-related Ashwagandha report found is a 2016 laboratory study, not a human trial. Withania somnifera root extract was applied for 72 hours to HeLa cervical-cancer cells, and TRAP-assay telomerase activity rose by about 45% at selected concentrations. Because HeLa cells already possess active telomerase and differ from normal adult tissues, this cannot show that oral Ashwagandha lengthens human telomeres, slows ageing, or extends life.

Human research does provide a different, narrower signal. Randomized trials and NIH reviews indicate that some Ashwagandha extracts may reduce perceived stress and cortisol and may improve sleep over short periods. Because stress and telomere biology can be associated observationally, stress reduction is a plausible research hypothesis, not proof of telomere preservation. The Ayurvedic Pharmacopoeia of India identifies the root of Withania somnifera and lists its properties as tikta-kashaya rasa, laghu guna, ushna virya, madhura vipaka, with Rasayana, balya, vajikarana, and Vata-Kapha-pacifying actions. These classical descriptors should remain distinct from modern molecular endpoints.

Amalaki: Classical Rasayana, No Verified Epigenetic Clock Trial

Amalaki or Amla is firmly documented as a Rasayana drug in the Ayurvedic Pharmacopoeia of India. For the fruit, the Pharmacopoeia lists five tastes—madhura, amla, katu, tikta, and kashaya—together with laghu and ruksha guna, shita virya, madhura vipaka, and actions including Rasayana and tridoshajit. It also names Cyavanaprasha as an important formulation. This supports Amalaki’s classical rejuvenative status without requiring a modern telomere claim.

Human trials of Phyllanthus emblica extracts have examined outcomes such as lipids, endothelial function, oxidative-stress markers, inflammation, and glucose-related measures. A 2023 systematic review and meta-analysis evaluated effects on lipid profile, glucose, and C-reactive protein. These findings may justify further cardiometabolic research, but antioxidant or lipid changes do not establish slower biological ageing, telomere lengthening, SIRT1 activation in humans, or increased lifespan.

Vitamin C content differs with cultivar, maturity, storage, processing, and assay. The Pharmacopoeia confirms ascorbic acid and tannins among Amalaki constituents but does not endorse a fixed “20-30 times orange” comparison.

Brahmi and Bacopa: Cognitive Research Is Not Telomere Research

Bacopa monnieri is widely marketed as Brahmi and has been studied in randomized trials for memory and cognitive performance, including a placebo-controlled study in healthy adults aged 65 or older. The available human Bacopa literature does not demonstrate telomere lengthening, senescent-cell clearance, or lifespan extension.

Classical naming also requires care. Both Bacopa monnieri and Centella asiatica have been called Brahmi in different regions and commercial contexts. In discussions of Charaka’s four Medhya Rasayana drugs, Mandukaparni is generally identified as Centella asiatica, while Guduchi is Tinospora cordifolia. It is therefore inaccurate to use a modern Bacopa extract trial as automatic confirmation of every classical reference to Brahmi or Mandukaparni.

Guduchi: Traditional Use Does Not Establish “Immunosenescence Reversal”

Guduchi is included in classical Medhya Rasayana discussions. Laboratory and animal studies describe immunomodulatory and anti-inflammatory effects, yet authoritative clinical reviews note that such activities have not been established as anti-ageing benefits in humans. There is no credible evidence that Guduchi reverses immune ageing or preserves lymphocyte telomeres.

Safety is especially important. Published case series and the NIH LiverTox monograph associate Tinospora cordifolia products with clinically apparent liver injury, often with autoimmune-like features, and risk may be greater in people with pre-existing liver disease. This does not erase its classical use, but it makes unsupervised long-term “immune boosting” or anti-ageing dosing inappropriate.

The Rasayana Framework and Modern Geroscience

Classical Ayurvedic physicians did not describe chromosomes, telomerase, DNA methylation clocks, FOXO3a, SIRT1, or mTOR. They described observed qualities, indications, preparation methods, eligibility, diet, conduct, and supervised use within an Ayurvedic model of dosha, agni, srotas, dhatu, and ojas. Modern geroscience can test herbs for defined outcomes, but shared interest in ageing does not prove shared mechanisms.

A responsible bridge between the systems asks testable questions: Is the botanical identity authenticated? Is the preparation standardized? Is the outcome measured in humans? Is the comparator appropriate? Are adverse events and interactions monitored? Are changes in a surrogate biomarker accompanied by meaningful improvements in function or disease risk? Without these steps, molecular language may make traditional claims sound more proven than they are.

Current Evidence by Herb or Formulation

The table distinguishes classical status from direct human evidence relevant to telomeres or validated ageing clocks. “No verified evidence” does not mean that a herb has no traditional value or no pharmacological activity; it means that the specific longevity claim has not been demonstrated in an adequate human study.

Herb or formulation	Verified classical or clinical basis	Direct human telomere/ageing-clock evidence	Responsible conclusion
Ashwagandha	API lists the root as Rasayana; short-term human trials address stress, cortisol, and sleep	No verified telomere-length RCT; one 2016 HeLa-cell telomerase experiment	Promising for selected non-longevity outcomes, not proven anti-ageing therapy
Amalaki	API lists Amalaki as Rasayana and an ingredient of Cyavanaprasha; human cardiometabolic trials exist	No verified epigenetic-clock or telomere trial	Classically important, but biological-age reversal is unproven
Bacopa monnieri	Human cognition trials exist	No verified FOXO3a, senescent-T-cell, telomere, or ageing-clock trial	Cognitive evidence cannot be relabelled as longevity evidence
Guduchi	Classical Medhya Rasayana use; mainly preclinical immune research	No verified immunosenescence-reversal or telomere trial	Unproven for longevity; liver-injury risk requires caution
Shatavari	Traditional use and limited condition-specific research	No verified human telomere or ageing-clock study	No evidence-based anti-ageing dose can be stated
Purified Shilajit	Traditional Rasayana use and limited human studies for selected outcomes	No verified telomere or validated biological-age trial	Quality control is essential; longevity claims remain unproven

The Chyawanprash Perspective

Cyavanaprasha is a classical Amalaki-based polyherbal Rasayana, commonly prepared with many plant ingredients plus ghee, sesame oil, sugar, and honey. Reviews describe roughly 50 ingredients, although formulas and commercial products vary.

Published human research is much more limited. A 2001 study compared 15 g daily of Chyawanprash with vitamin C in only ten healthy young men and assessed glucose tolerance and lipoproteins. A 2017 six-month randomized, open-label study in schoolchildren compared Chyawanprash plus milk with milk alone and recorded illness episodes and parent-reported health measures; some authors were employed by the manufacturer. Neither study measured telomeres, epigenetic age, senescence, or adult longevity. For broader background, see our article on Rasayana therapy and modern longevity research. Speculative discussion of CRISPR, Rasayana, and longevity should likewise be read as future-oriented analysis, not clinical guidance.

Practical Application

Current evidence does not support a five-product daily “anti-ageing stack,” universal doses for telomere protection, or the claim that six to twelve months of these products reverses biological age. The proposed combination has not been tested as a regimen, and combining products makes adverse effects, interactions, and quality problems harder to identify.

Base healthy-ageing plans on measures with established benefit: regular physical activity, a balanced diet, adequate sleep, avoidance of tobacco, limited or no alcohol, vaccination and screening appropriate to age, and good control of blood pressure, glucose, and lipids.
When an Ayurvedic herb is considered for a specific goal, use authenticated, quality-tested products and choose the formulation and duration with a qualified Ayurvedic practitioner and healthcare provider.
Avoid self-prescribing Guduchi for long-term immune or anti-ageing use, and stop any supplement promptly while seeking care if jaundice, dark urine, severe itching, persistent nausea, or unusual fatigue develops.
People who are pregnant or breastfeeding, have liver, thyroid, autoimmune, metabolic, or other chronic disease, take prescription medicines, or are preparing for surgery need individualized medical advice before supplementation.

This article is educational and does not diagnose, treat, prevent, or reverse ageing. Rasayana is a classical Ayurvedic framework, while telomere and epigenetic-clock claims require direct human evidence. Consult a qualified Ayurvedic practitioner and healthcare provider before beginning any long-term herbal or mineral preparation.

References

Mitochondrial Health Through Ayurvedic Rasayana: What Cell Energy Research Shows

Dr. Meera Iyer — Tue, 12 May 2026 09:00:00 +0000

When I first encountered the classical descriptions of Rasayana, I read them through the lens of pharmacognosy. Claims of longevity, memory, intelligence, freedom from illness, youthful qualities, strength, lustre, and clarity seemed too broad to translate into a single modern mechanism. The often-quoted list belongs to the Charaka Samhita, Chikitsa Sthana 1, not to a laboratory description of mitochondria or an exact quotation from the Ashtanga Hridaya.

Modern mitochondrial research nevertheless offers a legitimate area for comparison. Mitochondria participate in energy production, redox signalling, apoptosis, inflammation, and metabolic adaptation. That does not prove that classical authors were describing mitochondria, but it does justify asking whether particular Rasayana materials influence mitochondrial or oxidative-stress pathways in experimental models.

Some studies report effects on respiratory-chain enzymes, membrane potential, antioxidant systems, muscle adaptation, or exercise performance. Most are animal, cell, or small human studies, and several commonly repeated claims—direct CoQ10 cycling by shilajit, PGC-1α activation by multiple herbs, proven mitophagy from Guduchi, or mitochondrial rejuvenation in humans—are not established.

The Classical Rasayana Framework

Rasayana is counted among Ayurveda’s eight branches. In the opening chapter of the Charaka Samhita’s treatment section, it is described as a means of attaining excellent qualities of rasa and the succeeding dhatus. The passage associates Rasayana with longevity, memory, intelligence, freedom from disorder, youthfulness, strength, complexion, voice, and brilliance. These are classical therapeutic aims, not validated modern clinical outcomes.

Rasa dhatu should not be reduced to “blood plasma,” and the succession of seven dhatus should not be rewritten as a modern cellular nutrition pathway. Ayurveda uses its own functional language of agni, dosha, dhatu, srotas, suitability, preparation, and conduct. Biomedical concepts such as oxidative phosphorylation, mitochondrial DNA, and autophagy arise from a different explanatory system. Comparison may generate research questions, but identity claims obscure both traditions.

Charaka also makes Rasayana more than a supplement programme. The chapter describes indoor and outdoor modes of administration, emphasises preparation of the recipient, and states that prescribed methods succeed in a person whose body and mind have been properly prepared. Achara Rasayana adds truthfulness, nonviolence, calmness, cleanliness, measured sleep and waking, compassion, self-control, and respectful conduct. A four-capsule “mitochondrial stack” is not a classical Rasayana course.

Where Mitochondria Fit—and Where They Do Not

Mitochondria generate most cellular ATP through oxidative phosphorylation, but they are not merely batteries. They continually fuse, divide, alter their number, communicate with the nucleus, and are removed through quality-control pathways that include mitophagy. Ageing research examines impaired bioenergetics, dynamics, redox balance, quality control, inflammation, and cellular senescence. Mitochondrial dysfunction is one hallmark among several, not the single cause of ageing.

The older statement that mitochondrial DNA is “unprotected” and has almost no repair is also inaccurate. Mitochondrial DNA is packaged in nucleoids with proteins including mitochondrial transcription factor A, and mitochondria possess DNA-repair pathways. Mutations and damage can still accumulate, but the biology is more complex than a simple contrast between protected nuclear DNA and unprotected mitochondrial DNA.

Shilajit: Preclinical Mitochondrial Evidence, Limited Human Proof

Shilajatu or shilajit is a complex mineral-organic exudate, not a plant species; therefore “Asphaltum punjabianum” should not be treated as a modern botanical name. Charaka includes properly processed shilajatu in the Rasayana chapter and gives detailed processing and administration instructions. Neither the classical passage nor modern evidence establishes reversal of biological ageing in humans.

The most directly relevant experiment is a 2012 rat study of a processed, chemically standardised shilajit preparation in a forced-swim model of chronic fatigue. Investigators measured respiratory-chain complex activities and mitochondrial membrane potential in the prefrontal cortex and reported protection against stress-associated changes. This animal study cannot be converted directly into a human dose or longevity claim.

Human research is more indirect. A 2016 study reported skeletal-muscle gene-expression changes after oral shilajit in overweight or class-I obese adults. A 2019 randomised trial in recreationally active men tested 250 or 500 mg daily for eight weeks and measured fatigue-related strength loss and serum hydroxyproline, not ATP production, mitochondrial copy number, CoQ10 cycling, or PGC-1α. A cited fulvic-acid study was published in 2011 and affected tau aggregation in vitro; it was not a 2009 mitochondrial trial or an Alzheimer’s treatment trial.

Shilajit Quality and Dose Context

No single “standard dose” applies to every resin, powder, or extract because composition and standardisation differ. Published human studies can show what was tested, but they do not create a universal prescription. Classical shodhana and modern identity, contaminant, and batch testing answer different quality questions.

Evidence source	Material and amount studied	What was actually measured
2012 animal experiment	Standardised processed shilajit; weight-based rat doses	Brain respiratory-chain enzymes, membrane potential, oxidative-stress markers, and behaviour
2016 human transcriptome study	Oral standardised shilajit in overweight/class-I obese adults	Skeletal-muscle gene-expression responses
2019 human trial	250 or 500 mg daily for eight weeks	Fatigue-related muscular strength and serum hydroxyproline

Shilajit should be purchased only from a reputable source providing identity, microbial, pesticide, and heavy-metal testing. “Natural” or “classically purified” on a label is not a substitute for a certificate tied to the finished batch. Unidentified raw material and products making drug-like anti-ageing claims should not be self-administered.

Amalaki: Antioxidant Evidence Is Not Mitochondrial Rejuvenation

Āmalakī fruit has a prominent place in Charaka’s Rasayana formulations. The Ayurvedic Pharmacopoeia of India monograph lists it as Emblica officinalis Gaertn.; biomedical literature also commonly uses Phyllanthus emblica L. Its fruits contain tannins and other phenolic constituents, and preclinical work supports antioxidant activity. A 2002 animal study evaluated an emblicanin-enriched fraction and reported effects on oxidative-stress measures.

Human evidence remains indirect. In a 2013 randomised study involving people with type 2 diabetes, a standardised Phyllanthus emblica extract improved endothelial-function and oxidative-stress biomarkers over twelve weeks. That trial did not measure mitochondrial biogenesis, mitochondrial DNA damage, mitophagy, or “young” versus “aged” mitochondria.

Accordingly, Amalaki can accurately be discussed as a classical Rasayana ingredient with antioxidant and limited clinical biomarker evidence. It should not be advertised as a proven mitochondrial antioxidant therapy. Powder, fruit, juice, and extracts are not dose-equivalent, and honey or ghee is not suitable for everyone.

Ashwagandha: VO2 Max Is Not a Mitochondrial Biomarker

Aśvagandhā is identified in the Ayurvedic Pharmacopoeia as Withania somnifera Dunal. It is widely used in Ayurvedic practice for strength and restoration, but modern product extracts vary by plant part, extraction method, and withanolide profile. An eight-week study in elite Indian cyclists was published in 2012, while a 2015 trial involved healthy athletic adults over twelve weeks. Neither trial directly counted mitochondria or measured PGC-1α.

A 2020 systematic review selected five studies with 162 participants and concluded that ashwagandha might improve maximal oxygen uptake, while explicitly calling for further research. VO2 max is an integrated result of cardiac output, pulmonary function, blood oxygen transport, muscle perfusion, training status, motivation, and peripheral oxygen use. Improvement can be compatible with better metabolic performance, but it does not by itself demonstrate mitochondrial biogenesis.

There is therefore no verified basis for prescribing “300 mg twice daily for eight to twelve weeks” as a universal mitochondrial protocol or for claiming that ashwagandha and shilajit independently activate the same PGC-1α master switch in humans. Trial doses should remain attached to the exact extracts studied.

Guduchi: Animal Mitochondrial Findings and a Real Liver Warning

Guḍūcī, Tinospora cordifolia, appears in the classical Rasayana discussion, including among substances used for medhya purposes. Modern evidence does not verify that “tinospirone and cordycepin-like alkaloids” inhibit mTOR and induce human mitophagy. Cordycepin is characteristically associated with Cordyceps fungi, and no credible 2019 human immune-cell study matching the stated Guduchi claim was identified.

A relevant 2023 experiment used an ethanolic Tinospora cordifolia extract in rotenone-exposed mice. It reported changes in mitochondrial electron-transport-chain activity, membrane potential, oxidative stress, apoptosis-related proteins, and motor behaviour. That supports further preclinical investigation, not claims of human mitophagy, slower ageing, or Parkinson’s treatment.

Safety is especially important. LiverTox now regards Tinospora cordifolia as a well-established cause of clinically apparent liver injury, with reported cases ranging from enzyme elevations to severe hepatitis and acute liver failure, particularly in some people with pre-existing liver disease. This evidence rules out casual “400 mg daily” recommendations and argues strongly against unsupervised long-term use.

A Corrected Evidence Map

The following table separates classical placement, the strongest directly relevant modern evidence located, and what remains unproven. It is an evidence map, not a treatment protocol.

Material	Classical or pharmacopoeial basis	Most relevant modern evidence	Not established
Shilajit	Processed shilajatu described in Charaka’s Rasayana chapter	Rat mitochondrial-bioenergetics study; small human muscle studies	Human CoQ10 cycling, PGC-1α activation, anti-ageing efficacy
Amalaki	Major fruit in Charaka’s Rasayana formulations; API monograph	Preclinical antioxidant work; human endothelial and oxidative-stress biomarkers	Human mitochondrial rejuvenation or Nrf2 restoration of aged mitochondria
Ashwagandha	API monograph; traditional strength and restorative use	Small exercise trials and a limited VO2-max meta-analysis	Direct human mitochondrial biogenesis
Guduchi	Included in classical Rasayana discussion	Mouse evidence involving oxidative stress and mitochondrial function	Human mitophagy, mTOR-mediated longevity, or Parkinson’s treatment
Haritaki	Prominent in Charaka’s Rasayana chapter; API name Terminalia chebula Retz.	Laboratory research exists, but no verified human mitochondrial endpoint was identified here	A bedtime dose that reduces cellular senescence through NF-κB in humans

What the Research Still Does Not Show

There are not yet robust human trials showing that a classical Rasayana course increases mitochondrial DNA copy number, TFAM, muscle PGC-1α, respiratory capacity, or mitophagy while also improving clinically meaningful ageing outcomes. Performance, fatigue, antioxidant biomarkers, and gene-expression signals are not direct proof of mitochondrial renewal or longer life.

Lifestyle Foundations With Stronger Mitochondrial Evidence

Regular physical activity has substantially stronger human evidence for mitochondrial adaptation than any herb discussed here. A 2025 systematic review and meta-analysis found increased PGC-1α expression after endurance exercise, although study heterogeneity was high. Both continuous and interval training can contribute; intensity should reflect health and training status.

Exercise: Combine sustainable aerobic activity with resistance training rather than treating one heart-rate zone as a universal prescription.
Food and recovery: Adequate protein, micronutrients, energy intake, and recovery support training adaptation; severe restriction can impair it.
Sleep and regular timing: Consistent sleep and wake schedules support metabolic and circadian health, but the evidence does not justify claiming that mitochondrial repair “peaks” at a universal clock time.
Fasting and cold exposure: These remain active research areas. A fixed sixteen-hour fast or deliberate cold exposure should not be presented as necessary Rasayana care or as proven human mitophagy treatment.

The closer classical parallel is a disciplined regimen of food, routine, restraint, sleep, mental steadiness, and conduct. Even here, classical recommendations require interpretation for constitution, age, disease, climate, occupation, and contemporary medical needs.

Practical Safety and Consultation

Do not combine shilajit, Amalaki, ashwagandha, Guduchi, and Haritaki simply because each is called Rasayana in some context. Form, dose, vehicle, duration, indication, contraindications, and product quality matter. Ashwagandha can interact with medicines and is not advised in several situations, including pregnancy; rare liver injury has been reported. Guduchi has a clearer liver-injury signal. Mineral-containing or poorly controlled Ayurvedic products may also expose users to harmful heavy metals.

Research and safety note: The herb–mitochondria relationship is an evolving research field, not a validated anti-ageing protocol. Consult a qualified Ayurvedic practitioner and a healthcare professional before using Rasayana products, especially during pregnancy or breastfeeding, in children, with liver or kidney disease, autoimmune or thyroid disorders, before surgery, or while taking prescription medicines. Do not replace indicated medical treatment with these products.